Compare Icl Group Ltd (ICL) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Tempus AI — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.60B), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and Icl Group Ltd pays a 4.05% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Tempus AI for 22 Days on average.
| ICL | TEM | |
|---|---|---|
Market Cap | $6.60B | $12.77B |
Volume | 824,784 | 8,980,490 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $6.84 | $99.28 |
52-Week Low | $4.80 | $41.55 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | $9.24B | $13.40B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL Group trades at $5.00, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The company shows stable revenue around $7.2B but declining net margins from 21.55% in 2022 to 3.15% in 2025. Analyst consensus is neutral with 100% hold ratings and a $6.08 price target, suggesting 22% upside. Recent news highlights dividend strength and Q2 2026 earnings beat.
ICL offers value with low P/S (0.85) and EV/EBITDA (6.77) ratios, but faces profitability pressures from industry headwinds. The primary risk is margin compression from higher input costs, while institutional buying and dividend yield provide support. The stock presents a cautious opportunity for value investors willing to withstand sector volatility.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
